ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.33−0.09 (-0.79%)
Close on Nov 17, 2026Market cap $102.90MP/E 141.6Yield –
ImmuCell revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
ImmuCell's revenue for the twelve months ending Jun 30, 2026 was $30.68M, up 8.5% year over year. For fiscal 2025 it was $27.64M, up 4.3% from the year before. Over ten years it grew 10.5% a year on average. The highest annual figure on record is $27.64M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.64M | +4.3% |
| FY2024 | Dec 31, 2024 | $26.49M | +51.6% |
| FY2023 | Dec 31, 2023 | $17.47M | -5.9% |
| FY2022 | Dec 31, 2022 | $18.57M | -3.5% |
| FY2021 | Dec 31, 2021 | $19.24M | +25.4% |
| FY2020 | Dec 31, 2020 | $15.34M | +11.8% |
| FY2019 | Dec 31, 2019 | $13.72M | +24.9% |
| FY2018 | Dec 31, 2018 | $10.99M | +5.3% |
| FY2017 | Dec 31, 2017 | $10.43M | +9.3% |
| FY2016 | Dec 31, 2016 | $9.54M | -6.7% |
| FY2015 | Dec 31, 2015 | $10.23M | +34.6% |
| FY2014 | Dec 31, 2014 | $7.60M | +26.5% |
| FY2013 | Dec 31, 2013 | $6.01M | +11.5% |
| FY2012 | Dec 31, 2012 | $5.39M | +5.5% |
| FY2011 | Dec 31, 2011 | $5.11M | +16.5% |
| FY2010 | Dec 31, 2010 | $4.39M | -2.7% |
| FY2009 | Dec 31, 2009 | $4.51M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.19M | +11.5% |
| Q1 FY2026 | Mar 31, 2026 | $10.36M | +28.4% |
| Q4 FY2025 | Dec 31, 2025 | $7.63M | -1.6% |
| Q3 FY2025 | Sep 30, 2025 | $5.51M | -8.4% |
| Q2 FY2025 | Jun 30, 2025 | $6.44M | +17.8% |
| Q1 FY2025 | Mar 31, 2025 | $8.07M | +11.2% |
| Q4 FY2024 | Dec 31, 2024 | $7.75M | – |
| Q3 FY2024 | Sep 30, 2024 | $6.01M | +11.4% |
| Q2 FY2024 | Jun 30, 2024 | $5.47M | +54.9% |
| Q1 FY2024 | Mar 31, 2024 | $7.26M | +110.6% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $5.40M | +12.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.53M | -8.5% |
| Q1 FY2023 | Mar 31, 2023 | $3.45M | -42.6% |
| Q4 FY2022 | Dec 31, 2022 | $3.91M | -28.2% |
| Q3 FY2022 | Sep 30, 2022 | $4.80M | -6.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.86M | -15.0% |
| Q1 FY2022 | Mar 31, 2022 | $6.00M | +46.1% |
| Q4 FY2021 | Dec 31, 2021 | $5.44M | +45.4% |
| Q3 FY2021 | Sep 30, 2021 | $5.15M | +38.4% |
| Q2 FY2021 | Jun 30, 2021 | $4.54M | +53.1% |
| Q1 FY2021 | Mar 31, 2021 | $4.11M | -16.4% |
| Q4 FY2020 | Dec 31, 2020 | $3.74M | +3.1% |
| Q3 FY2020 | Sep 30, 2020 | $3.72M | +25.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.97M | +9.4% |
| Q1 FY2020 | Mar 31, 2020 | $4.91M | +11.3% |
| Q4 FY2019 | Dec 31, 2019 | $3.63M | +23.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.97M | +37.9% |
| Q2 FY2019 | Jun 30, 2019 | $2.71M | -10.1% |
| Q1 FY2019 | Mar 31, 2019 | $4.41M | +53.1% |
| Q4 FY2018 | Dec 31, 2018 | $2.94M | -6.2% |
| Q3 FY2018 | Sep 30, 2018 | $2.15M | +7.4% |
| Q2 FY2018 | Jun 30, 2018 | $3.01M | +72.3% |
| Q1 FY2018 | Mar 31, 2018 | $2.88M | -18.7% |
| Q4 FY2017 | Dec 31, 2017 | $3.13M | +41.5% |
| Q3 FY2017 | Sep 30, 2017 | $2.00M | +1.9% |
| Q2 FY2017 | Jun 30, 2017 | $1.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.54M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.21M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.97M | – |
See a number that looks wrong?